Clinical Trial Update: Immunotherapy +/- EGFR Inhibitor In Advanced/Metastatic cSCC: Tackling Primary And Secondary Resistance [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring immunotherapy with or without an EGFR inhibitor in advanced/metastatic cutaneous squamous cell carcinoma (cSCC) to address primar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Squamous Cell Carcinoma

Snippet

Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Conditions: Skin Neoplasm | Phase 2 | Status: UNKNOWN